Press Release: PHARMATEK DOUBLES API-IN-CAPSULE MANUFACTURING CAPACITY LEADING TO COST SAVINGS FOR CLIENTS
LIGHTNING RELEASES: SAN DIEGO, Calif. (4/24/2014) – Pharmatek, a contract development and manufacturing organization supporting the pharmaceutical industry, today announced the launch of the Company’s new API-in-capsule manufacturing program. The initiative, designed to meet industry demand for manufacturing strategies that lower development cost, aims to shorten timelines and increase capsule throughput for API-in-capsule productions.
Pharmatek has earned a reputation as a veteran provider of API-in-capsule having manufactured more than 90 API-in-capsule batches. Filling drug directly into capsules is one of the fastest ways to enter the clinic. The approach can reduce time and financial investment at the early phases.
“We have seen more and more clients push the envelope on how far they will take API-in-capsule in development. No longer is the technology seen as a Phase I-only solution,” said Pharmatek president Tim Scott. “And because micro-dose systems are not keeping up with the scale required for larger batches, we looked for ways to improve efficiencies, both in terms of reducing costs and speeding up processes.”
A key aspect of the program is the recent facility expansion, which includes two cGMP manufacturing suites designed specifically for API-in-capsule productions. Suite features include humidity control and inert gas systems, which contribute to a more robust manufacturing process for API-in-capsule productions. In addition to the customized suites, Pharmatek has implemented operational systems to further address efficiencies, including dedicated project teams; streamlined batch records; extended shift operations; redundant equipment and change parts; and on-demand inventory management. Combined, these efforts offer clients faster scheduling, turn-around time and speed to clinic for API-in-capsule CTM productions.
“By implementing the new API-in-capsule program, Pharmatek has increased capsule throughput and reduced production times by as much as 50%,” stated Pharmatek director of manufacturing, Kevin Rosenthal. “Additionally, the program has enabled Pharmatek to lower the overall cost of API-in-capsule productions and pass substantial savings on to our clients.”
Pharmatek is a dosage form development and GMP manufacturing company providing full-service pharmaceutical chemistry product development and manufacturing for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection; analytical development; preformulation testing; formulation development; GMP manufacturing; clinical packaging, labeling and distribution; stability storage and testing; and cytotoxic and high-potency drug development.
Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the web site http://www.pharmatek.com or by calling 858-805-6383.
This story was originally published by American Banking News (http://www.americanbankingnews.com) and is the sole property of American Banking News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.americanbankingnews.com/2014/04/24/pharmatek-doubles-api-in-capsule-manufacturing-capacity-leading-to-cost-savings-for-clients/
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.